{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:10Z","timestamp":1791414070586,"version":"4.3.3"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Efgartigimod (EFG), a neonatal Fc receptor antagonist that facilitates the degradation of pathogenic immunoglobulin G, is approved for the treatment of generalized myasthenia gravis (MG). This study aims to evaluate the efficacy and safety of EFG in patients with very-late-onset myasthenia gravis (VLOMG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study enrolled 15 consecutive patients diagnosed with VLOMG who received EFG treatment. Baseline demographic and clinical characteristics, as well as dynamic changes in the MG-specific activities of daily living (MG-ADL) score and quantitative MG (QMG) score, were systematically recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients were stratified into two groups: a worse group (n = 8) and a new-diagnosed group (n = 7), the latter of which included 5 patients who had received monotherapy with pyridostigmine (Py) prior to EFG. At week 5, the mean changes in MG-ADL scores were -4.9 \u00b1 3.3 in the overall VLOMG cohort, -6.1 \u00b1 3.1 in the new-diagnosed group, -6.6 \u00b1 3.6 in the mono-Py subgroup, and -3.8 \u00b1 3.2 in the worse group. The clinical meaningful improvement (CMI) rate was 86.7% (13\/15) in the overall cohort, 75.0% (6\/8) in the worse group, and 100.0% (7\/7) in the new-diagnosed group. During a mean follow-up time of 39.2 \u00b1 16.2 weeks, symptoms remained stable in responsive patients, with various treatment strategies implemented following the fast-acting treatment of EFG. No adverse drug reactions were reported in this cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates that EFG is an effective and safe treatment for patients with VLOMG. EFG exhibits potential as an early, fast-acting treatment and may confer sustained clinical benefits in this patient population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1579859","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:23:25Z","timestamp":1744867405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhouao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyou","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.02.013","article-title":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","volume":"33","author":"Tang","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-019-01252-x","article-title":"Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome","volume":"120","author":"Yildiz Celik","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41582-020-0345-3","article-title":"New insights into very-late-onset myasthenia gravis","volume":"16","author":"Barnett","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17562864241309793","DOI":"10.1177\/17562864241309793","article-title":"Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients","volume":"18","author":"Xie","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28893","article-title":"Clinical characteristics of\u00a0late-onset myasthenia gravis","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"B11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2010.484419","article-title":"Safety of intravenous immunoglobulin treatment","volume":"9","author":"Caress","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22002","article-title":"Plasma exchange in a bottle\": An overview of efgartigimod for apheresis practitioners","volume":"37","author":"Tran","year":"2022","journal-title":"J Clin Apher"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12883-024-03804-y","article-title":"Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report","volume":"24","author":"Ohara","year":"2024","journal-title":"BMC Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28178","article-title":"Efgartigimod infusion in the treatment regimen for myasthenic crisis: A case report","volume":"70","author":"Sun","year":"2024","journal-title":"Muscle Nerve"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: A review in generalised myasthenia gravis","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflammation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1018509","article-title":"Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis","volume":"13","author":"Duan","year":"2022","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.843523","article-title":"Efficacy and safety of tacrolimus therapy for a single chinese cohort with very-late-onset myasthenia gravis","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"key":"B27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of\u00a0molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur J Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"123264","DOI":"10.1016\/j.jns.2024.123264","article-title":"Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis","volume":"466","author":"Dewilde","year":"2024","journal-title":"J Neurol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1579859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:23:25Z","timestamp":1744867405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1579859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1579859"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1579859","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"article-number":"1579859"}}